LUCD - Lucid Diagnostics Inc.
Region: US
Website: luciddx.com
Employees: 0
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Medical Equipment/Surgical, Medical, And Dental Instruments And Supplies
Sector: Manufacturing
Lucid Diagnostics Inc. focuses on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux. The company was incorporated in 2018 and is based in New York, New York.
Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10, 2025 at 11:00 AM EDT.
Read moreLucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced a campaign, entitled "Embrace the Future", designed to showcase its groundbreaking EsoCheck® Esophageal Cell Collection Device, with Collect+Protect™ Technology, to gastroenterologists and the broader medical community. The campaign will coincide with Esophageal Cancer Awareness Month this April and will
Read morePAVmed Inc (PAVM) Q4 2024 Earnings Call Highlights: Strategic Growth and Financial Stability
PAVmed Inc (PAVM) reports significant growth in test volumes and revenue, while securing strategic partnerships and funding to bolster future operations.
Read more